Company news
Exicure, Inc. (NASDAQ:XCUR) news
Exicure, Inc. news releases on 6ix. Latest, Sep 1, 2022: Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
Press releases — page 2
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
August 31, 2022
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress
August 14, 2022
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 19, 2022
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split
June 28, 2022
Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders
May 26, 2022
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
May 16, 2022
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
May 15, 2022
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
May 9, 2022
Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference
May 8, 2022
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress
March 24, 2022
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors
February 3, 2022
Exicure, Inc. Announces $11.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
December 13, 2021
Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus
December 9, 2021
Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress
November 18, 2021
Exicure Files Form 12b-25
November 14, 2021
Exicure to Present at Upcoming Scientific Conferences
October 27, 2021
Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
October 3, 2021
Exicure to Present at the Benzinga Healthcare Small Cap Conference
September 22, 2021
Exicure to Participate in Upcoming Scientific Conferences
September 14, 2021
Exicure to Participate in Upcoming Investor Conferences
August 31, 2021
Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress
August 11, 2021
Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)
August 4, 2021
Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference
August 3, 2021
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
August 1, 2021
Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day
July 7, 2021
Exicure, Inc. to Present at Ladenburg Thalmann 2021 Healthcare Conference
June 28, 2021
Exicure, Inc. Announces Participation in Upcoming Conferences
June 2, 2021
Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)
May 12, 2021
Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress
May 11, 2021
Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress
March 10, 2021
Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors
March 8, 2021
Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod
March 2, 2021
Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
February 22, 2021
Exicure Announces Participation in 10th Annual SVB Leerink Global Healthcare Conference
February 8, 2021
Exicure Announces Presentation at 2021 BIO CEO & Investor Digital Conference
February 1, 2021
Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration
January 10, 2021
Exicure Announces Appointment of James Sulat to Board of Directors
January 4, 2021
Exicure Announces Agenda for Upcoming Neuroscience Pipeline Update at Virtual R&D Day
January 3, 2021
Exicure Announces Webcast of Presentation at 2021 HC Wainwright BIOCONNECT Conference
December 28, 2020
Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day
December 27, 2020
Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034
December 20, 2020
Exicure to Participate in Upcoming Conferences
November 15, 2020
Exicure, Inc. to Present at the virtual Fall Investor Summit on November 16th-18th
November 11, 2020
Exicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress
November 11, 2020
Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
November 8, 2020
Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
October 18, 2020
Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
October 4, 2020
Exicure Secures Debt Facility for Up to $25.0 Million
September 30, 2020
Exicure Presents Promising Interim Results from Ongoing Phase 1b/2 Trial of Cavrotolimod at Virtual KOL Event Today
September 15, 2020
Exicure to Present at Upcoming Conferences
September 9, 2020